A revolutionary new treatment for cataracts has shown extremely positive results in laboratory tests, giving hope that the condition, which currently can only be cured with surgery, could soon be treated with drugs.
Oertli's OS 4 platform is a powerful, multifaceted system designed for retinal, glaucoma, and cataract surgeries. At its core lies a 3-pump mechanism featuring vacuum and flow regulation, as well as a novel SPEEP pump.
AcuFocus announced that it has received an Approvable Letter from the FDA for its IC-8 small aperture IOL, which is designed for cataract patients.
LENSAR announced that the U.S. Food and Drug Administration (FDA) has accepted its 510(k) submission for its next-generation ALLY Adaptive Cataract Treatment System for substantive review.
Bilateral implantation of the Tecnis Synergy IOL showed “very good” performence at all distances at 3 months of follow-up.